The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope

• Published in: Rheumatology advances in practice Vol. 8; no. 2; p. rkae056
• Main Authors: Hannah, Jennifer, Rodziewicz, Mia, Mehta, Puja, Heenan, Kerri-Marie, Ball, Elizabeth, Barratt, Shaney, Carty, Sara, Conway, Richard, Cotton, Caroline V, Cox, Sarah, Crawshaw, Anjali, Dawson, Julie, Desai, Sujal, Fahim, Ahmed, Fielding, Carol, Garton, Mark, George, Peter, Gunawardena, Harsha, Kelly, Clive, Khan, Fasihul, Koduri, Gouri, Morris, Helen, Naqvi, Marium, Perry, Elizabeth, Riddell, Claire, Sieiro Santos, Cristiana, Spencer, Lisa G, Chaudhuri, Nazia, Nisar, Muhammad K
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 2024
• Subjects: Associations, institutions, etc; Care and treatment; Evidence-based medicine; Guideline; Lung diseases; Medical personnel; Pharmaceutical industry; Rheumatoid factor; Scleroderma (Disease); Societies; Systemic scleroderma; United Kingdom; Germany; interstitial lung disease; UK; guideline; scope; connective tissue disease
• ISSN: 2514-1775; 2514-1775
• DOI: 10.1093/rap/rkae056

Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.